Corona Accelerated R&D in Europe

Informazioni relative al progetto

CARE

ID dell’accordo di sovvenzione: 101005077

DOI

10.3030/101005077

Progetto chiuso

Data della firma CE 7 Agosto 2020

Data di avvio 1 Aprile 2020

Data di completamento 31 Marzo 2025

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 77 255 143,22

Contributo UE

€ 36 559 186,09

Coordinato da

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Other (3)

Reverse-engineered drug-resistant viruses

Collection of viruses that are produced by reverse-engineering to carry (a) mutation(s) that make them to (partially) resistant to the inhibitory effect of selective inhibitors

Coordinated AI-platform

Drive efficient compound designs for phenotypic and target-based programs

Analysis of targets for druggability

AI-platforms will enable selection of a portfolio of tractable targets. Data from multiple databases, will be used to build predictive models for developability criteria e.g., potency, selectivity, ADME-Tox using diverse algorithms e.g., Random Forrest. Design objectives will drive the AI-design platform

Demonstrators, pilots, prototypes (15)

A streamlined and efficient drug discovery testing cascade for CoVs

A compound testing cascade to accelerate decision making for drug discovery

A set of emergency/additional molecules

Emergency/Preparedness set of molecules for WP2

A toolbox with at least 8 assays

A toolbox with at least 8 assays able to measure binding and/or activity of the targeted proteins listed in task 2.6

Report on set up of the non-human primate model for SARS-CoV-2 infection and Report on set up of the non-human primate model for SARS-CoV-2 infection and diseaseease

A report or publication that summarizes the development and clinical manifestations in the NHP model. The report also will summarize various primary and secondary endpoint that will facilitate evaluation of the test compounds.

A HTS assay for the RTC under a 384 well plate format

A HTS assay for the RTC under a 384-well plate format suitable to expedite focused screening of inhibitors (M6) and hit-to-lead efforts

Harmonisation of SOP between WP6 partners and with WP1-7

SOP will be developed for prioritization of assets across various WPs, submitted and endorsed by the Steering Committee.

Optimised Lead 1

Delivery of optimised leads suitable for candidate selection within WP6

Crystal or Cryo-EM structures of the nsp14 and Spike protein

A crystal or cryo-EM structure of i) the nsp14 with or without the nsp10 co-factor at a resolution lower than 2.5 Å, allowing structure-guided inhibitor screening and design (M60); 2) the Spike protein either in complex with a peptidic/non-peptidic inhibitor or with different conformation along the fusion process

2-CARE Small Molecule (SM) system impact model

SM system quantitative impact model

Report on reverse genetics system

Report should detail methods, development of mouse adapted virus based on reverse genetics and evaluation of the virus in a murine model establishing, primary and secondary endpoints in a non-trangenic strain.

1-CARE Small Molecule (SM) system impact model

SM system conceptual impact model

Report on setting up of rodent models

A report to be written related to the rodent models to be used for testing of the 35 best candidates from WP1-4. 1. imported, characterised and bred K18 and humanised ACE-2 murine models in IVI and LUMC. 2. Characterised various Syrian Gold Hamster models in KU Leuven. Report should detail methods, controls used, primary and secondary endpoints and minimum results expected to show efficacy, as well as any processes to be used for PK/PD correlationsA report to be written related to the rodent models to be used for testing of the 35 best candidates from WP1-4. 1. imported, characterised and bred K18 and humanised ACE-2 murine models in IVI and LUMC. 2. Characterised various Syrian Gold Hamster models in KU Leuven] Report should detail methods, controls used, primary and secondary endpoints and minimum results expected to show efficacy, as well as any processes to be used for PK/PD correlations.

Optimised Lead 2

Delivery of optimised lead suitable for candidate selection within WP6

3-CARE Small Molecule (SM) system impact model

SM consortium system maps

Report on suitability of mouse adapted SARS-CoV-2 virus for lethal humanised ACE-2 model

Report will detail methods and evaluation of the mouse model, dose used, primary and secondary endpoints and minimum results expected to show efficacy.

Open Research Data Pilot (3)

Mid-term data Management Plan

Data management plan mid-term version at Month 36

End of project Data Management Plan

Data management plan end of project version

Initial Data Management Plan

An initial version of Data Management Plan will be prepared

Documents, reports (7)

2-Portfolio report

Update at Month 12 on progress to deliver optimised lead

4-Portfolio report

Update at Month 24 on progress to deliver optimised lead

Duo reporter HTS assay

Validated HTS assay based on a reporter virus and reporter cell line

1-Portfolio report

Update at Month 6 on progress to deliver optimised lead

3-Portfolio report

Update at Month 18 on progress to deliver optimised lead

Setup of the Clinical Trial Platform: Fast track process set up

Setup of a Clinical Trial platform: Fast track process is set up by M18

Setup of the Clinical Trial Platform: Implementation of representation concept completed

Setup of a Clinical Trial Platform: Implementation concept completed by M19.

Pubblicazioni

Peer reviewed articles (42)

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Autori: Craig Fenwick, Priscilla Turelli, Yoan Duhoo, Kelvin Lau, Cécile Herate, Romain Marlin, Myriam Lamrayah, Jérémy Campos, Line Esteves-Leuenberger, Alex Farina, Charlène Raclot, Vanessa Genet, Flurin Fiscalini, Julien Cesborn, Laurent Perez, Nathalie Dereuddre-Bosquet, Vanessa Contreras, Kyllian Lheureux, Francis Relouzat, Rana Abdelnabi, Pieter Leyssen, Yves Lévy, Florence Pojer, Roger Le Gran
Pubblicato in: Journal of infection, 2023, ISSN 0163-4453
Editore: W. B. Saunders Co., Ltd.
DOI: 10.1016/j.jinf.2023.10.008

A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection

Autori: Abdelnabi R, Foo CS, Kaptein SJF, Boudewijns R, Vangeel L, de Jonghe S, Jocmans D, Weynand B, Neyts J.
Pubblicato in: Journal of virology, 2022, ISSN 0022-538x
Editore: American Society for Microbiology
DOI: 10.1128/jvi.00758-22

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.

Autori: Obeid M, Suffiotti M, Pellaton C, et al.
Pubblicato in: JAMA Oncol., Numero 8/5, 2022, Pagina/e e220446, ISSN 2374-2445
Editore: American MEdical Association
DOI: 10.1001/jamaoncol.2022.0446

Modulation of nucleotide metabolism by picornaviruses

Autori: Lonneke V. Nouwen, Martijn Breeuwsma, Esther A. Zaal, Chris H. A. van de Lest, Inge Buitendijk, Marleen Zwaagstra,Pascal Balić, Dmitri V. Filippov, Celia R. Berkers, Frank J. M. van Kuppeveld
Pubblicato in: PloS Pathogens, 2024, ISSN 1553-7366
Editore: Public Library of Science
DOI: 10.1371/journal.ppat.1012036

A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein

Autori: Vito Thijssen, Daniel L Hurdiss , Oliver J Debski-Antoniak, Matthew A Spence, Charlotte Franck, Alexander Norman, Anupriya Aggarwal, Nadia J Mokiem, David A A van Dongen, Stein W Vermeir, Minglong Liu, Wentao Li, Marianthi Chatziandreou, Tim Donselaar, Wenjuan Du, Ieva Drulyte, Berend-Jan Bosch, Joost Snijder, Stuart G Turville, Richard J Payne, Colin J Jackson, Frank J M van Kuppeveld, Seino A K
Pubblicato in: PNAS, 2023, ISSN 0027-8424
Editore: National Academy of Sciences
DOI: 10.1073/pnas.2303292120

Challenges related to data protection in clinical research before and during the COVID-19 pandemic: An exploratory study

Autori: Lalova-Spinks T, De Sutter E, VAlcke P, Kindt E, Lejeune S, Negrouk A, Verhenneman G, Derèze JJ, Storme R, Borry P, Meszaros J, Huys I.
Pubblicato in: Frontiers in Medicine, 2022, ISSN 2296-858X
Editore: Frontiers Media S.A
DOI: 10.3389/fmed.2022.995689

An engineered A549 cell line expressing CD13 and TMPRSS2 is permissive to clinical isolate of human coronavirus 229E

Autori: LK Lie, A Synowiec, J Mazur, L Rabalski and K Pyrc
Pubblicato in: Virology, 2023, ISSN 0042-6822
Editore: Academic Press
DOI: 10.1016/j.virol.2023.109889

Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies

Autori: Craig Fenwick, Antony Croxatto, Alix T. Coste, Florence Pojer, Cyril André, Céline Pellaton, Alex Farina, Jérémy Campos, David Hacker, Kelvin Lau, Berend-Jan Bosch, Semira Gonseth Nussle, Murielle Bochud, Valerie D’Acremont, Didier Trono, Gilbert Greub, Giuseppe Pantaleo
Pubblicato in: Journal of Virology, Numero 95/3, 2021, ISSN 0022-538X
Editore: American Society for Microbiology
DOI: 10.1128/jvi.01828-20

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys

Autori: Craig Fenwick, Priscilla Turelli, Dongchun Ni, Laurent Perez, Kelvin Lau, Cécile Herate, Romain Marlin, Erica Lana, Céline Pellaton, Charlène Raclot, Line Esteves-Leuenberger, Jérémy Campos, Alex Farina, Flurin Fiscalini, Nathalie Dereuddre-Bosquet, Francis Relouzat, Rana Abdelnabi, Caroline S Foo, Johan Neyts, Pieter Leyssen, Yves Lévy, Florence Pojer, Henning Stahlberg, Roger LeGrand, Didi
Pubblicato in: Nature Microbiology, Numero 7(9), 2022, Pagina/e 1376-1389, ISSN 2058-5276
Editore: Nature Portfolio
DOI: 10.1038/s41564-022-01198-6

Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures

Autori: Winston Chiu,Lore Verschueren,Christel Van den Eynde,Christophe Buyck,Sandra De Meyer,Dirk Jochmans,Denisa Bojkova,Sandra Ciesek,Jindrich Cinatl,Steven De Jonghe,Pieter Leyssen,Johan Neyts,Marnix Van Loock,Ellen Van Damme
Pubblicato in: Journal of Medical Virology, Numero 94/7, 2022, Pagina/e 3101-3111, ISSN 1096-9071
Editore: Wiley
DOI: 10.1002/jmv.27683

Despite the odds: formation of the SARS-CoV-2 methylation complex

Autori: Alex Matsuda, Jacek Plewka, Michał Rawski, André Mourão, Weronika Zajko, Till Siebenmorgen, Leanid Kresik, Kinga Lis, Alisha N Jones, Magdalena Pachota, Abdulkarim Karim, Kinga Hartman, Shivlee Nirwal, Ravi Sonani, Yuliya Chykunova, Igor Minia, Paweł Mak, Markus Landthaler, Marcin Nowotny, Grzegorz Dubin, Michael Sattler, Piotr Suder, Grzegorz M Popowicz, Krzysztof Pyrć, Anna Czarna
Pubblicato in: Nucleic Acids Research, 2024, ISSN 0305-1048
Editore: Oxford University Press
DOI: 10.1093/nar/gkae165

SARS-CoV-2 Mpro oligomerization as a potential target for therapy

Autori: Kinga Lis, Jacek Plewka, Filipe Menezes, Ewa Bielecka, Yuliya Chykunova, Katarzyna Pustelny, Stephan Niebling, Angelica Struve Garcia, Maria Garcia-Alai, Grzegorz M. Popowicz, Anna Czarna, Tomasz Kantyka, Krzysztof Pyrc
Pubblicato in: International Journal of Biological Macromolecules, 2024, ISSN 0141-8130
Editore: Elsevier BV
DOI: 10.1016/j.ijbiomac.2024.131392

Neutralizing antibodies reveal cryptic vulnerabilities and interdomain crosstalk in the porcine deltacoronavirus spike protein

Autori: Wenjuan Du, Oliver Debski-Antoniak, Dubravka Drabek, Rien van Haperen, Melissa van Dortmondt, Joline van der Lee, Ieva Drulyte, Frank J. M. van Kuppeveld, Frank Grosveld, Daniel L. Hurdiss & Berend-Jan Bosch
Pubblicato in: Nature Communications, 2024, ISSN 2041-1723
Editore: Nature Publishing Group
DOI: 10.1038/s41467-024-49693-0

A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase

Autori: Ashleigh Shannon, Véronique Fattorini, Bhawna Sama, Barbara Selisko, Mikael Feracci, Camille Falcou, Pierre Gauffre, Priscila El Kazzi, Adrien Delpal, Etienne Decroly, Karine Alvarez, Cécilia Eydoux, Jean-Claude Guillemot, Adel Moussa, Steven S. Good, Paolo La Colla, Kai Lin, Jean-Pierre Sommadossi, Yingxiao Zhu, Xiaodong Yan, Hui Shi, François Ferron & Bruno Canard
Pubblicato in: Nature Communications, 2022, ISSN 2041-1723
Editore: Nature Publishing Group
DOI: 10.1038/s41467-022-28113-1

Assessment of Kinome-Wide Activity Remodeling upon Picornavirus Infection

Autori: Tim S. Veth, Lonneke V. Nouwen, Marleen Zwaagstra, Heyrhyoung Lyoo, Kathryn A. Wierenga, Bart Westendorp, Maarten A.F.M. Altelaar, Celia Berkers, Frank J.M. van Kuppeveld, Albert J.R. Heck
Pubblicato in: Molecular & Cellular Proteomics, 2024, ISSN 1535-9476
Editore: American Society for Biochemistry and Molecular Biology Inc.
DOI: 10.1016/j.mcpro.2024.100757

A highly potent antibody effective against SARS-CoV-2 variants of concern

Autori: Craig Fenwick, Priscilla Turelli, Laurent Perez, Céline Pellaton, Line Esteves-Leuenberger, Alex Farina, Jérémy Campos, Erica Lana, Flurin Fiscalini, Charlène Raclot, Florence Pojer, Kelvin Lau, Davide Demurtas, Marc Descatoire, Victor S. Joo, Mathilde Foglierini, Alessandra Noto, Rana Abdelnabi, Caroline S. Foo, Laura Vangeel, Johan Neyts, Wenjuan Du, Berend-Jan Bosch, Geertruida Veldman, Pie
Pubblicato in: Cell Reports, 2021, Pagina/e 109814, ISSN 2211-1247
Editore: Cell Press
DOI: 10.1016/j.celrep.2021.109814

Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2

Autori: Doijen J, Temmerman K, Van der Eynde C, Diels A, Van der Broeck N, Van Gool M, Heo I, Jaensch S, Zwaagstra M, Diosa Toro M, Chiu W, de Jonghe S, Leyssen P, Bojkova D, Ciesek S, Cinati J, Verschueren L, Buyck C, Van Kupeveld F, Neyts J, Van Loock M, Van DAmme E.
Pubblicato in: Microorganisms, 2023, ISSN 2076-2607
Editore: MDPI
DOI: 10.3390/microorganisms11030717

Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery

Autori: Winston Chiu, Joost Schepers, Thibault Francken, Laura Vangeel, Kayvan Abbasi, Dirk Jochmans, Steven De Jonghe, Hendrik Jan Thibaut, Volker Thiel, Johan Neyts, Manon Laporte, Pieter Leyssen
Pubblicato in: Antiviral Research, 2023, ISSN 0166-3542
Editore: Elsevier BV
DOI: 10.1016/j.antiviral.2022.105506

A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma

Autori: Craig Fenwick, Priscilla Turelli, Céline Pellaton, Alex Farina, Jérémy Campos, Charlène Raclot, Florence Pojer, Valeria Cagno, Semira Gonseth Nusslé, Valerie D’Acremont, Jan Fehr, Milo Puhan, Giuseppe Pantaleo, Didier Trono
Pubblicato in: Science Translational Medicine, Numero 13/605, 2021, Pagina/e eabi8452, ISSN 1946-6234
Editore: American Association for the Advancement of Science
DOI: 10.1126/scitranslmed.abi8452

Rethinking informed consent in the time of COVID-19: An exploratory survey

Autori: De Sutter E, Lalova-Spinks T, Borry P, Valcke P, Kindt E, Negrouk A, Verhenneman G, Derèze JJ, Storme R, Huys I
Pubblicato in: Frontiers in Medicine, 2022, ISSN 2296-858X
Editore: Frontiers Media S.A
DOI: 10.3389/fmed.2022.995688

Computed tomography and [18F]-FDG PET imaging provide additional readouts for COVID-19pathogenesis and therapies evaluation in non-human primates

Autori: Thibaut Naninck, Nidhal Kahlaoui, Julien Lemaitre, Pauline Maisonnasse, Antoine De Mori, Quentin Pascal, Vanessa Contreras, Romain Marlin, Francis Relouzat, Benoıt Delache, Cecile Herate, Yoann Aldon, Marit van Gils, Nerea Zabaleta, Raphael Ho Tsong Fang, Nathalie Bosquet, Rogier W. Sanders, Luk H. Vandenberghe, Catherine Chapon, and Roger Le Grand
Pubblicato in: IScience, Numero 25/4, 2022, Pagina/e 104101, ISSN 2589-0042
Editore: Cell Press, Elsevier
DOI: 10.1016/j.isci.2022.104101

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

Autori: Séverin Coléon, Aurélie Wiedemann, Mathieu Surénaud, Christine Lacabaratz, Sophie Hue, Mélanie Prague, Minerva Cervantes-Gonzalez, Zhiqing Wang, Jerome Ellis, Amandine Sansoni, Camille Pierini, Quentin Bardin, Manon Fabregue, Sarah Sharkaoui, Philippe Hoest, Léa Dupaty, Florence Picard, Marwa El Hajj, Mireille Centlivre, Jade Ghosn, French COVID Cohort Study Group, Rodolphe Thiébaut, Sylvai
Pubblicato in: EBioMedicine, Numero 80, 2022, Pagina/e 104062, ISSN 2352-3964
Editore: Elsevier BV
DOI: 10.1016/j.ebiom.2022.104062

A bivalent spike-targeting nanobody with anti-sarbecovirus activity

Autori: Iris C. Swart, Oliver J. Debski-Antoniak, Aneta Zegar, Thijs de Bouter, Marianthi Chatziandreou, Max van den Berg, Ieva Drulyte, Krzysztof Pyrć, Cornelis A. M. de Haan, Daniel L. Hurdiss, Berend-Jan Bosch, Sabrina Oliveira
Pubblicato in: Journal of Nanobiotechnology, Numero 23, 2025, ISSN 1477-3155
Editore: BioMed Central
DOI: 10.1186/s12951-025-03243-y

Comparing the Infectivity of Recent SARS-CoV-2 Omicron Sub-Variants in Syrian Hamsters

Autori: Rana Abdelnabi,Ria Lassaunière,Piet Maes,Birgit Weynand and Johan Neyts
Pubblicato in: Viruses, 2024, ISSN 1999-4915
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/v16010122

Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters

Autori: Abdelnabi R, Maes P, de Jonghe S, Weynand B, Neyts J.
Pubblicato in: Frontiers in Pharmacology, 2022, ISSN 1663-9812
Editore: Frontiers Media S.A.
DOI: 10.3389/fphar.2022.1072202

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

Autori: Bojkiva D, Reus P, Panosch L, Bechtel M, Rothenburger T, Kandler JD, Pfeiffer A, Wagner JUG, Shumliakivska M, Dimmeler S, Olmer R, Martin U, Vondran FWR, Toptan T, Rothweiler F, Zehner R, Rabenau HF, Osman KL, Pullan ST, Carroll MW, Cinatl Jr J.
Pubblicato in: iScience, 2023, ISSN 2589-0042
Editore: Cell Press Elsevier
DOI: 10.1016/j.isci.2023.105944

Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases.

Autori: Marcel Hausdorff, Adrien Delpal b, Sarah Barelier, Laura Nicollet, Bruno Canard, Franck Touret, Agathe Colmant, Bruno Coutard, Jean-Jacques Vasseur, Etienne Decroly, Françoise Debart
Pubblicato in: European Journal of Medecinal Chemistry, 2023, ISSN 0223-5234
Editore: Elsevier BV
DOI: 10.1016/j.ejmech.2023.115474

CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death

Autori: Yves Lévy, Aurélie Wiedemann, Boris P. Hejblum, Mélany Durand, Cécile Lefebvre, Mathieu Surénaud, Christine Lacabaratz, Matthieu Perreau, Emile Foucat, Marie Déchenaud, Pascaline Tisserand, Fabiola Blengio, Benjamin Hivert, Marine Gauthier, Minerva Cervantes-Gonzalez, Delphine Bachelet, Cédric Laouénan, Lila Bouadma, Jean-François Timsit, Yazdan Yazdanpanah, Giuseppe Pantaleo, Hakim Hocin
Pubblicato in: iScience, Numero 24/7, 2021, Pagina/e 102711, ISSN 2589-0042
Editore: Cell Press Elsevier Inc.
DOI: 10.1016/j.isci.2021.102711

CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses

Autori: Alessandra Noto, Victor Joo, Antonio Mancarella, Madeleine Suffiotti, Celine Pellaton, Craig Fenwick, Matthieu Perreau, Giuseppe Pantaleo
Pubblicato in: Viruses, Numero 14, 2025, Pagina/e 2665, ISSN 1999-4915
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/v14122665

Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19

Autori: Hakim Hocini, Aurélie Wiedemann, Fabiola Blengio, Cécile Lefebvre, Minerva Cervantes-Gonzalez, Emile Foucat, Pascaline Tisserand, Mathieu Surenaud, Séverin Coléon, Mélanie Prague, Lydia Guillaumat, Corinne Krief, Craig Fenwick, Cédric Laouénan, Lila Bouadma, Jade Ghosn, Giuseppe Pantaleo, Rodolphe Thiébaut; French COVID cohort study group; Yves Lévy
Pubblicato in: J Clin Immunol, 2023, ISSN 0271-9142
Editore: Kluwer Academic/Plenum Publishers
DOI: 10.1007/s10875-023-01459-x

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

Autori: Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, Andre E, Leyssen P, Neyts J and Jochmans D.
Pubblicato in: Antiviral Research, Numero 198, 2022, Pagina/e 105252, ISSN 0166-3542
Editore: Elsevier BV
DOI: 10.1016/j.antiviral.2022.105252

Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study

Autori: Yuao Zhu, Joe Binder, Irina Yurgelonis, Devendra K Rai, Sarah Lazarro, Chester Costales, Keith Kobylarz, Patricia McMonagle, Claire M Steppan, Lisa Aschenbrenner, Annaliesa S Anderson, Rhonda D Cardin
Pubblicato in: Antiviral Research, 2022, ISSN 0166-3542
Editore: Elsevier BV
DOI: 10.1016/j.antiviral.2022.105429

Refolding of lid subdomain of SARS-CoV-2 nsp14 upon nsp10 interaction releases exonuclease activity

Autori: Anna Czarna, Jacek Plewska, Leanid Kresik, Alex Matsuda, Abdulkarim Karim, Colin Robinson, Sean O'Byrne, Fraser Cunningham, Irene Georgiou, Piotr Wilk, Magdalena PAchota, Grzegorz Popowicz, Paul Graham Wyatt, Grzegorz Dublin, Krzystof Pyrc.
Pubblicato in: Structure, Numero 09692126, 2022, Pagina/e 1050-1054, ISSN 0969-2126
Editore: Cell Press
DOI: 10.1016/j.str.2022.04.014

Lack of Evidence of Angiotensin-Converting Enzyme 2 Expression and Replicative Infection by SARS-CoV-2 in Human Endothelial Cells

Autori: Ian R. McCracken, Gaye Saginc, Liqun He, Alik Huseynov, Alison Daniels, Sarah Fletcher, Claire Peghaire, Viktoria Kalna, Maarja Andaloussi-Mäe, Lars Muhl, Nicky M. Craig, Samantha J. Griffiths, Jürgen G. Haas, Christine Tait-Burkard, Urban Lendahl, Graeme M. Birdsey, Christer Betsholtz, Michela Noseda, Andrew H. Baker, Anna M. Randi
Pubblicato in: Circulation, Numero 143/8, 2021, Pagina/e 865-868, ISSN 0009-7322
Editore: Lippincott Williams & Wilkins Ltd.
DOI: 10.1161/circulationaha.120.052824

The application of data altruism in clinical research through empirical and legal analysis lenses

Autori: Teodora Lalova-Spinks, Janos Meszaros, Isabelle Huys
Pubblicato in: Frontiers in Medicine, 2023, ISSN 2296-858X
Editore: Lausanne Frontiers Media
DOI: 10.3389/fmed.2023.1141685

Synthesis, Structure–Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs As Inhibitors of SARS-CoV-2 Replication.

Autori: Dorothée Bardiot, Laura Vangeel, Mohamed Koukni, Philippe Arzel, Marleen Zwaagstra, Heyrhyoung Lyoo, Patrick Wanninge,n Shamshad Ahmad, Linlin Zhang, Xinyuanyuan Sun, Adrien Delpal, Cecilia Eydoux, Jean-Claude Guillemot, Eveline Lescrinier, Hugo Klaassen, Pieter Leyssen, Dirk Jochmans, Karolien Castermans, Rolf Hilgenfeld, Colin Robinso,n Etienne Decroly, Bruno Canard, Eric Snijder, Martijn Hemer
Pubblicato in: Molecules, Numero 27/3, 2022, Pagina/e 1052, ISSN 1420-3049
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/molecules27031052

Protection of K18-hACE2 Mice against SARS-CoV-2 Challenge by a Capsid Virus-like Particle-Based Vaccine

Autori: Sebenzile K. Myeni, Anouk A. Leijs, Peter J. Bredenbeek, Shessy Torres Morales, Marissa E. Linger, Cyrielle Fougeroux, Sophie van Zanen-Gerhardt, Serge A. L. Zander, Adam F. Sander, Marjolein Kikkert
Pubblicato in: Vaccines, Numero 12, 2025, Pagina/e 766, ISSN 2076-393X
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines12070766

Shape-Restrained Modeling of Protein–Small-Molecule Complexes with High Ambiguity Driven DOCKing

Autori: Panagiotis I. Koukos, Manon Réau, Alexandre M. J. J. Bonvin
Pubblicato in: Journal of Chemical Information and Modeling, Numero 61/9, 2021, Pagina/e 4807-4818, ISSN 1549-9596
Editore: American Chemical Society
DOI: 10.1021/acs.jcim.1c00796

Effective, but Safe? Physiologically Based Pharmacokinetic (PBPK)-Modeling-Based Dosing Study of Molnupiravir for Risk Assessment in Pediatric Subpopulations

Autori: Sarang Mishra, Katharina Rox
Pubblicato in: ACS Pharmacology & Translational Science, Numero 7, 2024, Pagina/e 4112-4122, ISSN 2575-9108
Editore: American Chemical Society (ACS)
DOI: 10.1021/acsptsci.4c00535

A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects

Autori: Jordi Doijen, Inha Heo, Koen Temmerman, Peter Vermeulen, Annick Diels, Steffen Jaensch, Mark Burcin, Nick Van den Broeck, Valerie Raeymaekers, Joren Peremans, Katrien Konings, Maxime Clement, Danielle Peeters, Marnix Van Loock, Anil Koul, Christophe Buyck, Michiel Van Gool, Ellen Van Damme
Pubblicato in: Antiviral Research, 2023, ISSN 0166-3542
Editore: Elsevier BV
DOI: 10.1016/j.antiviral.2023.105789

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

Autori: Ashleigh Shannon, Barbara Selisko, Nhung-Thi-Tuyet Le, Johanna Huchting, Franck Touret, Géraldine Piorkowski, Véronique Fattorini, François Ferron, Etienne Decroly, Chris Meier, Bruno Coutard, Olve Peersen, Bruno Canard
Pubblicato in: Nature Communications, Numero 11, 2022, ISSN 2041-1723
Editore: Nature Publishing Group
DOI: 10.1038/s41467-020-18463-z

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Autori: Pauline Maisonnasse, Jérémie Guedj, Vanessa Contreras, Sylvie Behillil, Caroline Solas, Romain Marlin, Thibaut Naninck, Andres Pizzorno, Julien Lemaitre, Antonio Gonçalves, Nidhal Kahlaoui, Olivier Terrier, Raphael Ho Tsong Fang, Vincent Enouf, Nathalie Dereuddre-Bosquet, Angela Brisebarre, Franck Touret, Catherine Chapon, Bruno Hoen, Bruno Lina, Manuel Rosa Calatrava, Sylvie van der Werf, Xavi
Pubblicato in: Nature, Numero 585/7826, 2020, Pagina/e 584-587, ISSN 0028-0836
Editore: Nature Publishing Group
DOI: 10.1038/s41586-020-2558-4

Conference proceedings (2)

Future-Proofing European Regulatory and Market Access Practices Based on Learnings From the COVID-19 Pandemic – Stakeholder Perspectives

Autori: Z Claessens, G Beirne, C Decouttere, N Vandaele, I Huys, L Barbier
Pubblicato in: Value in Health, 2022
Editore: Elsevier
DOI: 10.1016/j.jval.2022.09.1333

How Are Patient Experience Data Reported in Regulatory Evaluation of Medicinal Products? A Document Analysis of European Public Assessment Reports

Autori: C. Verbeke, J. Cuppens, I. Huys, L. Barbier, R. Janssens
Pubblicato in: Value in Health, 2023
Editore: Elsevier
DOI: 10.1016/j.jval.2023.09.1456

Other (1)

High Throughput cryo-EM epitope mapping of SARS-CoV-2 spike protein antibodies using EPU multigrid

Autori: Ieva Drulyte, Stefan Koester, Dianna Lundberg, Kurt Eng, Andrey Malyutin, Aaron McGrath, Chunyan Wang, Frank van Kuppeveld, Berend-Jan Bosch, Mazdak Radjainia, Jerry Thomas, Maureen Magnay and Daniel Hurdiss
Pubblicato in: 2022
Editore: ThermoFischer